Evidence map›Paper›PMID 36278104›Full record

ReviewACS omega2022

Functionalized Peptide-Based Nanoparticles for Targeted Cancer Nanotherapeutics: A State-of-the-Art Review.

Ritika Sharma, Shikha Jyoti Borah, Bhawna, Sanjeev Kumar, Akanksha Gupta, Poonam Singh, Vijay Kumar Goel, Ravinder Kumar, Vinod Kumar

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. A Stable Delivery System forMarine drugs · 2025
    Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ritika SharmaDepartment of Biochemistry, University of Delhi, Delhi 110021, India.
Shikha Jyoti BorahSpecial Centre for Nano Sciences, Jawaharlal Nehru University, Delhi 110067, India.
BhawnaDepartment of Chemistry, University of Delhi, Delhi 110007, India.
Sanjeev KumarDepartment of Chemistry, University of Delhi, Delhi 110007, India.
Akanksha GuptaDepartment of Chemistry, Sri Venkateswara College, University of Delhi, Delhi 110007, India.ORCID https://orcid.org/0000-0003-1398-2085
Poonam SinghDepartment of Applied Chemistry, Delhi Technological University, Delhi 110042, India.
Vijay Kumar GoelSchool of Physical Science, Jawaharlal Nehru University, Delhi 110067, India.
Ravinder KumarDepartment of Chemistry, Gurukula Kangri (Deemed to be University), Haridwar 249404, Uttarakhand, India.
Vinod KumarSpecial Centre for Nano Sciences, Jawaharlal Nehru University, Delhi 110067, India.ORCID https://orcid.org/0000-0002-8362-8009

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer mortality is increasing at an alarming rate across the globe. Albeit, many therapeutics are available commercially, they are not effective and have no cure up to today. Moreover, the knowledge gap in cancer therapy persists, representing a potential blind spot for the innovation of effective anticancer therapeutics. This review presents an update on current advancements in nanopeptide therapeutics. Herein, a detailed exploration of peptide-functionalized nanoparticles for the development of nanotherapeutics was carried out. Different approaches that include self-assembly nanostructures, solid phase peptide synthesis, ligand exchange, chemical reduction, and conjugation methods for assembling peptides for functionalizing nanodrugs are also highlighted. An outlook on biomedical applications is also reviewed. Additionally, a comprehensive discussion on targeted cancer cell therapy and mechanism of action are provided. The present review reflects the functional novelty of nanodrugs to improve stability, accessibility, bioavailability, and specificity toward cancerous cells. Finally, it summarizes the current challenges and future perspectives on the formulation of these nanodrugs.

Identifiers

PMID36278104
PMCPMC9583493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.